The condition is primarily categorized into two clinical entities: hemophilia A, associated with mutations in the F8 gene encoding coagulation factor VIII, and hemophilia B, resulting from pathogenic variants in the F9 gene responsible for factor IX synthesis. This evidence concerns the gene F9 and hemophilia B.